Bifogade filer
BICO Q1 2025 ENG
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
BICO Group AB 559050–5052 (NASDAQ STOCKHOLM: BICO)
Further reduced debt in a quarter impacted by uncertain macro-economic dynamics
“Like many of our peers we saw continued uncertain macro-economic dynamics in Q1. For example, changes to US policy focus, and reduced NIH funding resulted in slower academic purchases. There were also industry cutbacks in CapEx budgets and the potential tariffs instilled further insecurity in the market. This made customers reluctant to make CapEx investments which impacted sales. Lab Automation faced fewer project starts and closures in combination with a high comparison quarter, while we saw positive development in Life Science Solutions and Bioprinting. After the end of the quarter, BICO entered into an agreement to divest MatTek and Visikol for USD 80m. The divestment follows the updated strategy with a focus on lab automation and selected workflows. The proceeds will be used to resolve the convertible bond, and we expect a positive net cash position during Q2 2025”, says Maria Forss, President and CEO, BICO Group AB.
January-March 2025 (compared with January-March 2024)
- Net sales amounted to SEK 388.6m (470.2) which corresponds to a decrease of −17.3% compared to the corresponding quarter previous year
- Organic sales growth for the quarter amounted to −19.0% (4.3%)
- The gross margin amounted to 54.0% (44.5%)
- Adjusted EBITDA amounted to SEK −12.3m (−6.6) corresponding to a margin of −3.2% (−1.4%)
- EBITDA amounted to SEK −13.8m (−15.5) corresponding to a margin of −3.5% (−3.3%)
- Net profit/loss for the quarter from continuing operations amounted to SEK −235.1m (−20.2) corresponding to earnings per share from continuing operations after dilution of SEK −3.33 (−0.27)
- Cash flow from operating activities amounted to SEK 76.6m (−17.3)
Q1 2025 takeaways
- Life Science Solutions and Bioprinting showed growth in sales and EBITDA margin thanks to commercial and operational excellence activities conducted in 2024 primarily in CELLINK and SCIENION
- Lab Automation impacted by fewer project starts and closures in combination with a high comparison quarter
- Continued uncertain macro-economic dynamics e.g., changes to US policy focus and reduced NIH funding resulted in slower academic purchases. There were also industry cutbacks in CapEx budgets and the potential tariffs instilled further insecurity in the market
- Tariff task force established to ensure proactive preparedness
- Completed repurchase of convertible bonds to a nominal value of SEK 276m in February 2025
Significant events after Q1 2025
- BICO entered an agreement to divest MatTek and Visikol to Sartorius for USD 80m. The closing of the transaction is subject to customary regulatory approvals which are expected to be obtained during
Q2 2025
Presentation for media and investors
A telephone conference, with the opportunity to ask questions, will be held later today, on April 29, 2025, at 10:00am CEST, at which President & CEO Maria Forss and CFO Jacob Thordenberg will present the interim report.
The presentation will be available on BICO’s website from 09:00am CEST.
https://bico.com/investors/
If you wish to participate via webcast, please use the link below:
https://bico.events.inderes.com/q1-report-2025
If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://conference.inderes.com/teleconference/?id=5004715